Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Status:
Completed
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
We conducted a single-center, prospective randomized ,Parallel controls, open labels Clinical
Studies,The study is about Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1
Inhibitor for Patients with malignant Advanced Solid Tumors .One group was the inosine group
, the other group was the non-inosine group.The treatment regimen of inosine group : inosine
+ PD-1/PD-L1 inhibitor ± chemotherapy/targeting, and the treatment regimen of non-inosine
group : PD-1/PD-L1 inhibitor ± chemotherapy/targeting.The primary study endpoints were
overall survival (OS) and progression-free survival PFS, and the secondary study endpoints
were objective remission rate (ORR) and disease control rate (DCR) comparing the two groups.